MedTrace Logo

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 589

Last updated 2014-10-16

Study results available
· View outcomes & findings →

Summary

To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes

Conditions

  • Diabetes, Type I

Interventions

DRUG

Technosphere Insulin

Inhalation, 15U/30U

DRUG

Active comparator

sc injectable insulin

Sponsors & Collaborators

  • Mannkind Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-07-31
Completion
2008-08-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Mexico
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308308 on ClinicalTrials.gov